In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Von Eschenbach named by Bush as FDA commissioner - but when will post begin?

This article was originally published in Clinica

Executive Summary

President Bush yesterday named acting FDA commissioner and family friend Andrew von Eschenbach to lead the agency on a permanent basis.

You may also be interested in...



FDA Re-Evaluates Orange Book Patents

With an eye toward addressing uncertainty as to whether patents that cover drug products’ device components or risk management elements should be listed, the agency seeks input on the need for additional clarity around the types of patents that must be submitted and the impact of any change in listing practices on drug development.

Mylan And Lupin Prepare To Launch EU Etanercept

Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.

FTC Notifies ReJuvenation ‘Anti-Aging’ Pill Purchasers To Expect (Or Request) Mailed Refunds

The sellers of the anti-aging “cure-all” reached an agreement with the FTC in February that prohibits them from making false and unsubstantiated health claims and requires them to pay $660,000 in total to the Commission. Refund checks now are being issued to more than 1,300 defrauded consumers.

Topics

UsernamePublicRestriction

Register

SC141604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel